Groupe d'Etude en Oncologie du Quebec

Titre	A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy
Protocole ID	KRYSTAL-10
ClinicalTrials.gov ID	NCT04793958
Type(s) de cancer	Colorectal
Phase	Phase III
Type étude	Clinique
Médicament	MRTX849 en association avec le cétuximab versus une chimiothérapie
Institution	CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX 5415 boul. de l'Assomption, Montréal, QC, H1T2M4
Ville	Montréal
Investigateur(trice) principal(e)	Dr Mikaël Soucisse
Coordonnateur(trice)	Audrey Lamoureux 514-252-3400 poste 6258
Statut	Fermé
Date d'activation	20-07-2022
Critètes d'éligibilité	Histologically confirmed diagnosis of colorectal carcinoma with KRAS G12C mutation in tumor tissue. Prior receipt of 1st line treatment in advanced CRC with a fluoropyrimidine-based chemotherapy regimen containing either oxaliplatin or irinotecan, and radiographically documented progression of disease on or after treatment.
Critètes d'exclusion	Prior treatment with a therapy targeting KRAS G12C mutation (e.g., AMG 510). Prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab). Active brain metastasis

Groupe d'étude en oncologie du Québec